Table 2.
Response Among All Eligible Patients With Measurable Adenocarcinoma Receiving ≥ One Cycle of Chemotherapy (N = 200)
| Response | No. (%) | ||
|---|---|---|---|
| EFC-C (n = 63) | IC-C (n = 71) | FOLFOX-C (n = 66) | |
| CR | 1 (1.5) | 1 (1.4) | 2 (3.0) |
| PR | 37 (58.7) | 31 (43.6) | 33 (50.0) |
| SD | 14 (22.2) | 23 (32.4) | 18 (27.2) |
| PD | 5 (7.9) | 11 (15.5) | 8 (12.1) |
| Not assessed | 2 (3.2) | 2 (2.8) | 4 (6.0) |
| Unknown | 4 (6.3) | 3 (4.2) | 1 (1.5) |
| ORR, % | 60.3 | 45.1 | 53.0 |
| 95% CI | 47.2 to 72.4 | 33.2 to 57.3 | 42.5 to 68.1 |
| Response duration, months | |||
| Median | 7.1 | 6.5 | 6.6 |
| Range | 1.1-65.8 | 0.5-26.5 | 2.4-60.1 |
Abbreviations: CR, complete response; ECF-C, epirubicin, cisplatin, and fluorouracil plus cetuximab; FOLFOX-C, oxaliplatin, leucovorin, and fluorouracil plus cetuximab; IC-C, irinotecan and cisplatin plus cetuximab; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.